Stockscreener 앱 받기
5.4129
2.08%
-0.1071
전일 마감가:
$5.52
열려 있는:
$5.57
하루 거래량:
42.75M
Relative Volume:
1.13
시가총액:
$2.32B
수익:
$64.60M
순이익/손실:
$-377.75M
주가수익비율:
-3.4922
EPS:
-1.55
순현금흐름:
$-335.64M
1주 성능:
-14.21%
1개월 성능:
-1.55%
6개월 성능:
-5.18%
1년 성능:
-15.55%
1일 변동 폭
$5.33
$5.76
1주일 범위
$5.33
$6.25
52주 변동 폭
$3.79
$12.36
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.425 | 2.41B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.84 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
640.39 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.34 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.23 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.98 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards? - Zacks Investment Research
How to interpret RSI for Recursion Pharmaceuticals Inc. stockTreasury Yields & Proven Capital Preservation Tips - newser.com
Using Bollinger Bands to evaluate Recursion Pharmaceuticals Inc.Recession Risk & Real-Time Stock Price Movement Reports - newser.com
Will earnings trigger a reversal in Recursion Pharmaceuticals Inc.July 2025 Fed Impact & High Yield Stock Recommendations - newser.com
Is Recursion Pharmaceuticals Inc. stock poised for growthWeekly Trade Recap & Reliable Breakout Stock Forecasts - newser.com
Will Recursion Pharmaceuticals Inc. stock maintain growth storyQuarterly Portfolio Report & Smart Money Movement Alerts - newser.com
Biotech Stocks To Add to Your WatchlistOctober 30th - MarketBeat
How Recursion Pharmaceuticals Inc. stock valuations compare to rivalsDollar Strength & Free Reliable Trade Execution Plans - newser.com
Is it time to cut losses on Recursion Pharmaceuticals Inc.July 2025 News Drivers & Daily Profit Maximizing Tips - newser.com
Top Biotech Stocks To Follow TodayNovember 1st - MarketBeat
Can Recursion Pharmaceuticals Inc. stock hit record highs againStock Surge & Real-Time Market Sentiment Alerts - newser.com
Recursion Pharmaceuticals (RXRX) Stock: CEO Sells $5.8 Million in Shares Following Exscientia Merger - CoinCentral
Top Biotech Stocks To Keep An Eye OnOctober 28th - MarketBeat
Best Biotech Stocks To Follow TodayOctober 31st - MarketBeat
Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Partnerships - Quiver Quantitative
Signal strength of Recursion Pharmaceuticals Inc. stock in tech scannersGlobal Markets & Free High Return Stock Watch Alerts - newser.com
Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? - The Globe and Mail
Has Recursion Pharmaceuticals Inc. formed a bullish divergenceVolume Spike & Real-Time Price Movement Reports - newser.com
BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia - Fierce Biotech
Earnings Preview: Recursion Pharmaceuticals (RXRX) Q3 Earnings Expected to Decline - sharewise.com
How Recursion Pharmaceuticals Inc. stock reacts to bond yieldsJuly 2025 PreEarnings & Community Shared Stock Ideas - newser.com
Recursion Pharmaceuticals Incannounces Roche's exercise of option for Microglia MapSEC filing - MarketScreener
Roche Exercises Option with Recursion Pharmaceuticals - TipRanks
Recursion Pharmaceuticals Announces Roche's Option Exercise - TradingView
Published on: 2025-10-29 07:02:21 - newser.com
Recursion Pharmaceuticals (RXRX) to Release Quarterly Earnings on Wednesday - MarketBeat
Is Hindustan Media Ventures Limited Stock Poised for a Breakout in YEARVolume Weighted Average Price & Master Stock Selection - earlytimes.in
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors - sharewise.com
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Recursion Pharmaceuticals, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators - Markets Mojo
Recursion Pharmaceuticals (RXRX): Exploring Valuation as AI Expansion, Key Merger, and Clinical Progress Boost Interest - simplywall.st
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th - MarketScreener
Recursion (NASDAQ: RXRX) to host Nov 5 (L)earnings call at 8:00 am ET, livestreamed - Stock Titan
IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Holdings in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Sumitomo Mitsui Trust Group Inc. Reduces Stock Position in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Will Recursion Pharmaceuticals Inc. stock benefit from sector rotationJuly 2025 Setups & Smart Investment Allocation Tips - fcp.pa.gov.br
Recursion Pharmaceuticals Inc. stock volume spike explainedJuly 2025 Weekly Recap & Real-Time Chart Pattern Alerts - newser.com
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.21%
1.56%
자본화:
|
볼륨(24시간):